No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NVO Novo-Nordisk A/S
- 135.280
- +2.480+1.87%
Close May 31 16:00 ET
- 135.620
- +0.340+0.25%
Post 19:58 ET
602.82BMarket Cap46.78P/E (TTM)
135.860High133.760Low3.45MVolume135.040Open132.800Pre Close464.68MTurnover0.11%Turnover Ratio50.03P/E (Static)4.46BShares137.29052wk High41.96P/B431.52BFloat Cap74.66252wk Low1.37Dividend TTM3.19BShs Float137.290Historical High1.01%Div YieldTTM1.58%Amplitude-3.084Historical Low134.833Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
SA Asks: Which Weight-loss Stocks Should Investors Be Watching?
'Stick With What's Working' as Markets Head Into June Trade: Fundstrat's Tom Lee
Goldman Sachs raised expectations for the size of the global diet pills market: Shuangxiongli is more optimistic about Lilly (LLY.US)
The Zhitong Finance App learned that Goldman Sachs believes that the potential of the global diet pills market will continue to grow. Goldman Sachs analysts led by Chris Shibutani said that the diet drug market currently dominated by Novo Nordisk (NVO.US) and LLY.US (LLY.US) may reach 130 billion US dollars by 2030. Previously, the bank's forecast scale was 100 billion US dollars. Currently, more and more drug developers are competing to tap the potential of the diet medicine market. At the same time, established leaders are also continuously expanding their share. The increase in industry size predictions further highlights the rapid development trend of the diet medicine market. Goldman Sachs column
Top Gap Ups and Downs on Thursday: CRM, SAP, NOW and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Ro CEO on GLP-1 Drug Shortage: US Healthcare Is '1 of 1'
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk
The recently launched Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) is gaining traction among investors, primarily due to its significant holdings in pharmaceutical giants Eli Lilly and Co (NYSE:LLY
Comments
$Novo-Nordisk A/S(NVO.US$ time for rebound to ATH?
follow me to earn money!
1. Q: Your goal is to be the best stock fund. How do you select stocks?
A: To be clear, the best stock fund refers to risk-adjusted performance. Hot stocks may perform better in the short term, just like some hot stocks during the epidemic, but they may eventually return to calm.
2. Q: So how do you select stocks to achieve this goal?
A: We have many criteria. First, we look for companies with high returns on investment (ROIC or ROIE). Th...
1. Q: Your goal is to be the best stock fund. How do you select stocks?
A: To be clear, the best stock fund refers to risk-adjusted performance. Hot stocks may perform better in the short term, just like some hot stocks during the epidemic, but they may eventually return to calm.
2. Q: So how do you select stocks to achieve this goal?
A: We have many criteria. First, we look for companies with high returns on investment (ROIC or ROIE). Th...
5
Interesting both for the (1) shift in the macro-trend to M&A (vs. Licensing) and (2) change in top spenders
$Merck & Co(MRK.US$ $Bristol-Myers Squibb(BMY.US$ $Johnson & Johnson(JNJ.US$ $Pfizer(PFE.US$ $Novo-Nordisk A/S(NVO.US$ $AbbVie(ABBV.US$
$Merck & Co(MRK.US$ $Bristol-Myers Squibb(BMY.US$ $Johnson & Johnson(JNJ.US$ $Pfizer(PFE.US$ $Novo-Nordisk A/S(NVO.US$ $AbbVie(ABBV.US$
10
1
$Viking Therapeutics(VKTX.US$ yes company very cheap considering how much total market valuations the other three companies have achieved from just GLP-1 market (Obesity) contribution alone
$Eli Lilly and Co(LLY.US$ easily 400+ Billion valuation from Obesity drug
$Novo-Nordisk A/S(NVO.US$ 50-100 Billion if not wrong
$Amgen(AMGN.US$ 20+ Billion on no data yet
$Eli Lilly and Co(LLY.US$ easily 400+ Billion valuation from Obesity drug
$Novo-Nordisk A/S(NVO.US$ 50-100 Billion if not wrong
$Amgen(AMGN.US$ 20+ Billion on no data yet
1
1
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
